Laboratories

print

Liquid Biopsy Diagnosis Development Project

Update : 2022-11-10

Overview

Liquid Biopsy Development Group

画像

imageLiquid biopsy, which involves genomic profiling of tumors using circulating biomarkers in the bodily fluid, has attracted tremendous interest in the field of cancer diagnosis and management. Liquid biopsy is advantageous in that sampling is minimally invasive and easily accessible through a simple blood draw, making repeated sampling possible. Longitudinal monitoring with liquid biopsy enables evaluation of tumor dynamic changes reflecting real-time disease status. In addition, liquid biopsy genomic profiling can capture both intratumor and intertumor heterogeneity, overcoming limitations of conventional tumor tissue genomic profiling. Our group focuses on circulating tumor DNA (ctDNA), which is highly degraded DNA fragments released from tumor cells. These DNA fragments recapitulate the tumor’s molecular profiles.

Projects

Our group collaborates closely with clinicians to perform various translational clinical studies with large number of blood samples using next generation sequencing approaches. The objectives of our group are:

  1. To evaluate the clinical utilities of liquid biopsy in cancer management as follow:
    1. ctDNA detection from liquid biopsy in various solid tumor
    2. minimal residual disease assessment among solid tumors
    3. Monitoring of therapeutic responsiveness
    4. Early detection of disease progression or relapse
    5. Genomic profiling of liquid biopsy for targeted therapy selection.
  2. To decipher the ctDNA characteristics via multi-omics approaches
    1. Fragmentomics analyses
    2. Epigenomics analyses
  3. ctDNA analyses of non-blood liquid biopsy

Publications

  1. Watanabe K, Nakamura T, Kimura Y, Motoya M, Kojima S, Kuraya T, Murakami T, Kaneko T, Shinohara Y, Kitayama Y, Fukuda K, Hatanaka KC, Mitsuhashi T, Pittella-Silva F, Yamaguchi T, Hirano S, Nakamura Y, Low SK.
    Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer.
    Int J Mol Sci. 2022 Sep 29;23(19):11521.
  2. Chan HT, Chin YM, Low SK.
    Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges.
    Cancers (Basel). 2022 Jul 4;14(13):3275.
  3. Low SK, Ariyasu R, Uchibori K, Hayashi R, Chan HT, Chin YM, Akita T, Harutani Y, Kiritani A, Tsugitomi R, Manabe R, Ogusu S, Amino Y, Kitazono S, Yanagitani N, Nakamura Y, Nishio M.
    Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer.
    Transl Lung Cancer Res. 2022 May;11(5):711-721.
  4. Chin YM, Shibayama T, Chan HT, Otaki M, Hara F, Kobayashi T, Kobayashi K, Hosonaga M, Fukada I, Inagaki L, Ono M, Ito Y, Takahashi S, Ohno S, Ueno T, Nakamura Y, Low SK.
    Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.
    Cancer Sci. 2022 May;113(5):1808-1820.
  5. Nagayama S, Low SK, Kiyotani K, Nakamura Y.
    Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy.
    Cancers (Basel). 2021 Sep 25;13(19):4803.
  6. Pittella-Silva F, Kimura Y, Low SK, Nakamura Y, Motoya M.
    Amplification of mutant KRASG12D in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report.
    Mol Clin Oncol. 2021 Sep;15(3):172.
  7. Watanabe K, Nakamura Y, Low SK.
    Clinical implementation and current advancement of blood liquid biopsy in cancer.
    J Hum Genet. 2021 Sep;66(9):909-926.
  8. Chin YM, Takahashi Y, Chan HT, Otaki M, Fujishima M, Shibayama T, Miki Y, Ueno T, Nakamura Y, Low SK.
    Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
    Cancer Sci. 2021 Jan;112(1):454-464.
  9. Chan HT, Chin YM, Nakamura Y, Low SK.
    Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications.
    Cancers (Basel). 2020 Aug 14;12(8):2277.
  10. Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S, Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I, Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M, Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K, Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H, Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y, Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M, Kamatani Y.
    Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases.
    Nat Genet. 2020 Jul;52(7):669-679.
  11. Pittella-Silva F, Chin YM, Chan HT, Nagayama S, Miyauchi E, Low SK, Nakamura Y.
    Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?
    Clin Chem. 2020 Jul 1;66(7):946-957.
  12. Chan HT, Nagayama S, Chin YM, Otaki M, Hayashi R, Kiyotani K, Fukunaga Y, Ueno M, Nakamura Y, Low SK.
    Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy.
    Mol Oncol. 2020 Aug;14(8):1719-1730.
  13. Shibayama T, Low SK, Ono M, Kobayashi T, Kobayashi K, Fukada I, Ito Y, Ueno T, Ohno S, Nakamura Y, Takahashi S.
    Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Apr;180(2):331-341.
  14. Low SK, Chin YM, Ito H, Matsuo K, Tanikawa C, Matsuda K, Saito H, Sakurai-Yageta M, Nakaya N, Shimizu A, Nishizuka SS, Yamaji T, Sawada N, Iwasaki M, Tsugane S, Takezaki T, Suzuki S, Naito M, Wakai K, Kamatani Y, Momozawa Y, Murakami Y, Inazawa J, Nakamura Y, Kubo M, Katagiri T, Miki Y.
    Identification of two novel breast cancer loci through large-scale genome-wide association study in the Japanese population.
    Sci Rep. 2019 Nov 22;9(1):17332.
  15. Low SK, Nakamura Y.
    The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy.
    Jpn J Clin Oncol. 2019 Jul 1;49(7):596-603.

Contact

Siew-Kee Amanda Low (Group Leader)
Liquid Biopsy Development Group,
Liquid Biopsy Diagnosis Development Project,
Cancer Precision Medicine Center, Japanese Foundation for Cancer Research
3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan
Tel: +81-3-3520-0111 (Extension 5625)
Fax: +81-3-3570-0644
E-mail: siewkee.low@jfcr.or.jp

Return to Top of Page